UK markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.9850+0.0050 (+0.13%)
As of 12:56PM EDT. Market open.

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400
https://www.herontx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees302

Key executives

NameTitlePayExercisedYear born
Dr. Barry D. Quart Pharm.D.Chairman & CEO1.1MN/A1957
Mr. John W. PoyhonenPres & Chief Commercial Officer722.35kN/A1960
Mr. David L. SzekeresExec. VP & COO710.66kN/A1974
Ms. Lisa PerazaVP & Chief Accounting Officer474.1kN/A1977
Ms. Kimberly J. ManhardExec. VP of Drug Devel. & Director739.8kN/A1960
Mr. Sean T. RistineSr. VP of HRN/AN/A1970
Dr. Thomas B. Ottoboni Ph.D.Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational SciencesN/AN/A1959
Mr. Michael E. MathewsSr. VP of Acute CareN/AN/A1963
Dr. Chris M. StorgardChief Medical OfficerN/AN/A1966
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Corporate governance

Heron Therapeutics, Inc.’s ISS governance QualityScore as of 1 September 2022 is 3. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.